Ultragenyx Pharmaceutical Inc. Ratios

Ratios Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
Gross Margin 99.96%97.77%91.31%97.74%95.44%92.21%89.59%86.30%
EBT Margin -184,841.35%-12,187.52%-398.95%-385.40%-69.90%-129.57%-193.60%-140.12%-101.31%
EBIT Margin -186,471.43%-12,593.49%-721.18%-408.98%-121.80%-108.63%-178.60%-131.08%-95.67%
EBITDA Margin -186,471.43%-12,593.49%-721.18%-408.98%-121.80%-108.63%-178.60%-131.08%-95.67%
Operating Margin -186,471.43%-12,593.49%-721.18%-408.98%-121.80%-108.63%-178.60%-131.08%-95.67%
Net Margin -184,867.67%-11,567.30%-399.95%-388.56%-70.34%-129.87%-195.62%-139.70%-101.84%
FCF Margin -128,693.98%-9,825.27%-572.18%-356.96%-64.98%-117.18%-136.68%-119.53%-75.27%
Efficiency
Inventory Average 3.91M9.31M12.30M14.64M21.50M30.37M39.49M
Assets Average 515.69M605.16M927.53M1,447.53M1,640.98M1,533.92M1,518.23M1,497.23M
Equity Average 428.71M496.18M631.34M904.07M1,038.47M637.53M313.95M265.36M
Invested Capital 473.97M383.45M608.91M653.76M1,154.38M922.56M352.49M275.41M255.30M
Asset Utilization Ratio 0.010.090.110.190.210.240.290.37
Leverage & Solvency
Equity Ratio 0.880.780.850.580.660.610.230.180.17
Dividends & Payouts
FCF Payout Ratio -0.09
Valuation
Enterprise Value 1,399.71M4,356.48M2,492.71M1,740.79M1,739.50M1,712.17M7,248.88M4,991.57M2,500.23M3,349.50M3,281.90M
Market Capitalization 1,399.71M4,356.48M2,872.86M1,975.28M2,199.20M2,467.40M8,450.42M5,731.76M3,247.99M3,926.71M3,884.92M
Return Ratios
Return on Sales -115.67%-4.00%-3.89%-0.70%-1.30%-1.96%-1.40%-1.02%
Return on Capital Employed -0.74%-0.70%-0.51%-0.26%-0.26%-0.51%-0.46%-0.46%
Return on Invested Capital -0.73%-1.81%
Return on Assets -0.59%-0.34%-0.43%-0.13%-0.28%-0.46%-0.40%-0.38%
Return on Equity -0.70%-0.42%-0.64%-0.21%-0.44%-1.11%-1.93%-2.15%